10x Genomics, Inc.

NasdaqGS:TXG Lagerbericht

Marktkapitalisierung: US$2.1b

10x Genomics Management

Management Kriterienprüfungen 3/4

10x Genomics CEO ist Serge Saxonov , ernannt in Jul 2012, hat eine Amtszeit von 12.33 Jahren. Die jährliche Gesamtvergütung beträgt $8.29M , bestehend aus 6.6% Gehalt und 93.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 3.33% der Aktien des Unternehmens, im Wert von $69.80M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.8 Jahre bzw. 5.4 Jahre.

Wichtige Informationen

Serge Saxonov

Geschäftsführender

US$8.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts6.6%
Amtszeit als Geschäftsführer12.3yrs
Eigentum des Geschäftsführers3.3%
Durchschnittliche Amtszeit des Managements2.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder5.4yrs

Jüngste Management Updates

Recent updates

Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

Nov 01
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

10x Genomics: Deciphering The Preliminary Q3 Earnings

Oct 12

The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%

Oct 11
The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%

10x Genomics Is Still A Long Way From Profitability

Oct 03

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Sep 09
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

Aug 10
Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

10x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead

Jul 10

10x Genomics: Sticking To The Plan To Avoid The Falling The Knife

Jun 21

Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

Jun 14
Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

May 21
10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Apr 15
Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Feb 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

10x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses

Jan 20

Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

Dec 22
Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Nov 03
We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

Jun 04
Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

Apr 29
At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 24
10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Feb 02
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

Jan 12
Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Dec 22
An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Serge Saxonov im Vergleich zu den Einnahmen von 10x Genomics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$183m

Jun 30 2024n/an/a

-US$240m

Mar 31 2024n/an/a

-US$264m

Dec 31 2023US$8mUS$545k

-US$255m

Sep 30 2023n/an/a

-US$223m

Jun 30 2023n/an/a

-US$172m

Mar 31 2023n/an/a

-US$174m

Dec 31 2022US$19mUS$504k

-US$166m

Sep 30 2022n/an/a

-US$167m

Jun 30 2022n/an/a

-US$142m

Mar 31 2022n/an/a

-US$89m

Dec 31 2021US$12mUS$430k

-US$58m

Sep 30 2021n/an/a

-US$455m

Jun 30 2021n/an/a

-US$504m

Mar 31 2021n/an/a

-US$533m

Dec 31 2020US$11mUS$400k

-US$543m

Sep 30 2020n/an/a

-US$134m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$2mUS$394k

-US$31m

Sep 30 2019n/an/a

-US$100m

Jun 30 2019n/an/a

-US$105m

Mar 31 2019n/an/a

-US$105m

Dec 31 2018US$1mUS$366k

-US$112m

Vergütung im Vergleich zum Markt: SergeDie Gesamtvergütung ($USD8.29M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD5.54M).

Entschädigung vs. Einkommen: SergeDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Serge Saxonov (47 yo)

12.3yrs

Amtszeit

US$8,286,050

Vergütung

Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Serge Saxonov
Co-Founder12.3yrsUS$8.29m3.33%
$ 69.8m
Benjamin Hindson
Co-Founder12.3yrsUS$4.43m2.68%
$ 56.2m
Eric Whitaker
Chief Legal Officer7.3yrsUS$3.88m0.12%
$ 2.5m
Adam Taich
CFO, Treasurerless than a yearkeine Datenkeine Daten
Jim Goodrich
Chief of Global Operationsless than a yearkeine Datenkeine Daten
Michael Schnall-Levin
Founding Scientist & CTO2.8yrskeine Datenkeine Daten
Alexander Wong
Chief Information Officerless than a yearkeine Datenkeine Daten
Cassie Corneau
Manager of Investor Relations & Strategic Financeno datakeine Datenkeine Daten
Rebecca Port
Chief People Officer3.8yrskeine Datenkeine Daten
Mennah Moustafa
Chief Commercial Officerless than a yearkeine Datenkeine Daten
Jens Durruthy
Associate Director of Product Managementno datakeine Datenkeine Daten

2.8yrs

Durchschnittliche Betriebszugehörigkeit

48.5yo

Durchschnittliches Alter

Erfahrenes Management: TXGDas Führungsteam des Unternehmens gilt als erfahren (2.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Serge Saxonov
Co-Founder12.3yrsUS$8.29m3.33%
$ 69.8m
Benjamin Hindson
Co-Founder12.3yrsUS$4.43m2.68%
$ 56.2m
Kimberly Popovits
Independent Director4.7yrsUS$338.71k0.0038%
$ 80.0k
John Stuelpnagel
Independent Chairman11.3yrsUS$403.59k2.02%
$ 42.3m
Shehnaaz Suliman
Independent Director5.3yrsUS$336.39k0.0038%
$ 80.0k
Alan Mateo
Directorless than a yearkeine Datenkeine Daten
Sridhar Kosaraju
Independent Director5.6yrsUS$346.39k0.029%
$ 614.6k
Sarah Polonius-Teichmann
Directorless than a yearkeine Datenkeine Daten

5.4yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrener Vorstand: TXGDie Vorstandsmitglieder gelten als erfahren (5.4 Jahre durchschnittliche Amtszeit).